EXPERIMENTAL TISSUE SHARED RESOURCE

实验组织共享资源（ETR）的主要目标是为癌症中心的基础，翻译和临床研究人员提供对人类和动物组织的访问和分析。一个关键的优势是，该核心利用病理学和实验室医学系的技术和专业知识。目前提供三种服务：i）组织组织学和免疫组织化学; ii）组织库; iii）组织分析，包括激光捕获显微镜、形态测定和图像定量以及基因分型服务。自上一个资助期启动核心项目以来，已有63个CFCCC成员使用了该项目，使用量有所增加，特别是在组织学/免疫组织化学部分，这部分占ETR内的大部分使用量。在上一个资助期内，组织学部分以低于市场的收费率为52个不同的CFCCC成员提供高质量的服务，这些成员主要从事人类癌症标本的转化研究或研究人类癌症的啮齿动物模型。在有需要时，我们会提供量身定制的服务，以满足CFCCC会员的特殊需求。这些功能使我们的组织学服务比商业供应商提供的服务更上级，从而促进了使用量的增长。ETR服务在上一个资助期内为43篇出版物做出了贡献，其中36篇使用了组织学服务。21名CFCCC研究者使用了组织库服务。15名研究人员使用的分析服务对从事转化和临床研究项目的研究人员特别有价值。在这次更新中，我们建议扩大以满足对组织学服务的需求，保持我们的专业分析服务，通过专注于全面的前列腺癌银行业务来加强我们的组织采购活动，并提供新的小鼠病理学服务，这将有助于CFCCC研究人员对人类癌症基因工程小鼠模型进行初步表征。

The primary objective of the Experimental Tissue Shared Resource (ETR) is to provide basic, translational, and clinical researchers within the Cancer Center access to, and analysis of, human and animal tissues. A key advantage is that this Core leverages the technical and professional expertise of the Department of Pathology and Laboratory Medicine. Three services are currently offered: i) tissue histology and immunohistochemistry; ii) tissue banking; and iii) tissue analysis, including laser capture microscopy, morphometry and image quantitation and genotyping services. Since the Core was initiated in the prior funding period, 63 CFCCC Members have used it. There has been growth in use, especially in the histology/immunohistochemistry component, which accounts for the majority of usage within the ETR. In the prior funding period, the histology component has provided high-quality service at below-market recharge rates, with short turn-around times to 52 different CFCCC Members who are mainly pursuing translational research on human cancer specimens or studying rodent models of human cancer. When required, we customized services to meet the special needs of CFCCC Members. These features have made our histology services superior to those available from commercial vendors, contributing to usage growth. ETR services contributed to 43 publications in the prior funding period, including 36 using histology services. Tissue banking services were used by 21 CFCCC investigators. Analytical services, used by 15 investigators, have been particularly valuable to investigators pursuing translational and clinical research projects. In this renewal, we propose to expand to meet an increased demand for histology services, maintain our specialty analytical services, strengthen our tissue procurement activities by focusing on comprehensively banking prostate cancers and provide a new mouse pathology service which will assist CFCCC investigators in the initial characterization of genetically engineered mouse models of human cancer.